• Publications
  • Influence
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Summary Background Surgical resection alone is regarded as the standard of care for patients with liver metastases from colorectal cancer, but relapse is common. We assessed the combination ofExpand
  • 1,505
  • 88
  • PDF
Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients
Five‐year survival rates after resection of liver metastases from colorectal carcinoma are close to 25%. Recurrences occur in two‐thirds of the patients after surgery. Selection of patients likely toExpand
  • 1,523
  • 49
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
PURPOSE Mutations within the KRAS proto-oncogene have predictive value but are of uncertain prognostic value in the treatment of advanced colorectal cancer. We took advantage of PETACC-3, an adjuvantExpand
  • 921
  • 49
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.
Colorectal cancer (CRC) is the most common tumour type in both sexes combined in Western countries. Although screening programmes including the implementation of faecal occult blood test andExpand
  • 990
  • 44
  • PDF
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
E. Van Cutsem1, A. Cervantes2, B. Nordlinger3 & D. Arnold4, on behalf of the ESMO Guidelines Working Group* Digestive Oncology, University Hospitals Leuven, Leuven, Belgium; Department of HematologyExpand
  • 652
  • 31
  • PDF
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Labianca1, B. Nordlinger2, G. D. Beretta3, S. Mosconi1, M. Mandalà1, A. Cervantes4 & D. Arnold5 on behalf of the ESMO Guidelines Working Group* Ospedale Papa Giovanni XXIII, Bergamo, Italy;Expand
  • 524
  • 25
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
BACKGROUND Previous results of the EORTC intergroup trial 40983 showed that perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) increases progression-free survivalExpand
  • 575
  • 24
  • PDF
Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases
Objective:To assess the effects of preoperative systemic chemotherapy on remnant liver parenchyma, liver function, and morbidity after major liver resection for colorectal liver metastases.Expand
  • 623
  • 19
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and
PURPOSE To compare the efficacy and tolerability of etoposide, leucovorin, and bolus fluorouracil (ELF) or infusional fluorouracil plus cisplatin (FUP) with that of the reference protocol ofExpand
  • 514
  • 19
Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up.
Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up R. Labianca, B. Nordlinger, G. D. Beretta, A. Brouquet & A. Cervantes On behalf of the ESMOExpand
  • 285
  • 19